<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02765464</url>
  </required_header>
  <id_info>
    <org_study_id>5160026</org_study_id>
    <nct_id>NCT02765464</nct_id>
  </id_info>
  <brief_title>Acute Kidney Injury in Critically Ill Patients</brief_title>
  <official_title>Predicting Acute Kidney Injury in Critically Ill Trauma Patients Using Metalloproteinase 2 (TIMP2) and Insulin-like Growth Factor Binding Protein7 (IGFBP 7)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute kidney injury (AKI) in critically ill trauma patients has been shown to significantly&#xD;
      increase mortality, length of stay, and costs, however detection has proven difficult as&#xD;
      markers like elevated creatinine and decreased urine output may take days to manifest and are&#xD;
      late indicators of AKI. The combination of two urinary biomarkers, Tissue Inhibitor of&#xD;
      Metalloproteinase 2 (TIMP-2) and Insulin-like Growth Factor Binding Protein 7 (IGFBP-7), has&#xD;
      been shown to increase within 12 hours following renal insult, allowing assessment of risk&#xD;
      for developing acute kidney injury. Therefore, the investigators plan to assess if acute&#xD;
      kidney injury in critically ill trauma patients can be determined earlier using urinary&#xD;
      TIMP-2 and IGFBP-7 via the NephroCheck testing system. These markers have not been&#xD;
      specifically evaluated in trauma patients at risk of AKI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2016</start_date>
  <completion_date type="Actual">November 30, 2019</completion_date>
  <primary_completion_date type="Actual">November 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of u rinary metalloproteinase 2 (TIMP-2) and Insulin-like growth factor binding protein 7 (IGFBP-7) biomarker elevation that corresponds to acute kidney injury by creatinine and urine output</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <enrollment type="Actual">50</enrollment>
  <condition>Acute Renal Injury</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects must be trauma patients with multiple injuries.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  trauma patients with multiple injuries;&#xD;
&#xD;
          -  abdominal injuries;&#xD;
&#xD;
          -  crush injuries;&#xD;
&#xD;
          -  those who present in shock (systolic blood pressure &lt;90 or mean arterial pressure&#xD;
             &lt;65);&#xD;
&#xD;
          -  require blood transfusions, vasopressors or mechanical ventilation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known pregnancy;&#xD;
&#xD;
          -  patients under 21 years of age;&#xD;
&#xD;
          -  known moderate to severe AKI prior to enrollment and end stage renal disease. known&#xD;
             moderate to severe AKI prior to enrollment and end stage renal disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronak Raval, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loma Linda University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 4, 2016</study_first_submitted>
  <study_first_submitted_qc>May 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2016</study_first_posted>
  <last_update_submitted>October 24, 2021</last_update_submitted>
  <last_update_submitted_qc>October 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loma Linda University</investigator_affiliation>
    <investigator_full_name>Ronak Raval</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

